
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics is a medical technology company that has reported strong gross margin growth and continues to develop its channel. Additionally, the company has revised their estimates and needs additional capital to fund operations. They have the potential for growth through accretive acquisitions and partnerships with sleep centers, showcasing early promise with their SCN integration. However, risks to their share price target include balance sheet and liquidity risks, as well as competition and changing market factors.
Bears say
Vivos Therapeutics is facing challenges with their transition from a legacy VIP/dentist model to the sleep-center model, leading to weakness in revenue growth in Q4. Additionally, their financials show a steady increase in shares outstanding, indicating the potential need for more financing in the near future. While their revenue did grow in 2025, there are concerns about their ability to compete in the market, secure capital and achieve sustainable profitability. The company must also address operational challenges and potential share dilution in order to meet previously projected growth.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares